Neurocrine Bioscienc (NQ: NBIX )
145.69
+1.55
(+1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Headline News about Neurocrine Bioscienc
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_7618.png?width=1200&height=800&fit=crop)
Expert Ratings for Neurocrine Biosciences
March 30, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2022/04/medical-device-stocks-hospital-stocks-healthcare-stocks.jpg)
![](/next-assets/images/schema-image-default.png)
Analyst Expectations for Neurocrine Biosciences's Future
March 03, 2023
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2022/08/Stock-neurocrinebio-01-shutt.jpg)
![](/next-assets/images/schema-image-default.png)
Neurocrine Biosciences Earnings Preview
February 03, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/717332/gene-therapy.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://www.valuewalk.com/wp-content/uploads/2023/01/Rural-Healthcare-768x384.jpeg)
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
Via Talk Markets
![](/next-assets/images/schema-image-default.png)
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image_94.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/02/03/krtx_logo_light__5ab4f4e09bf3f82a517f93702cc13b5a.png?width=1200&height=800&fit=crop)
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2020/10/cheap-stocks.jpg)
![](https://www.investors.com/wp-content/uploads/2021/08/Stock-BullPaintedRushing-adobe.jpg)
![](https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/01/09/2.0-voyager-pipeline_desktop-patient-resources_circle.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/25/aapharma.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/01/Stock-climberSilo-01-shutt.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/07/nbix_logo_light__12134bbdd373277108445dcfedb2f189.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/23/screenshot_2022-11-23_at_7.14.20_pm.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2022/11/Stock-neurologybrain-02-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_22686.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/14/image18.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/roce_image_3479.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-02-gov.jpg)
![](https://www.investors.com/wp-content/uploads/2022/08/Stock-neurocrinebio-01-shutt.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_1765.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_27899.jpeg?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_9169.jpeg?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.